TY - JOUR
T1 - Class II two-peptide lanthipeptide proteases
T2 - exploring LicTP for biotechnological applications
AU - Barbosa, Joana C.
AU - Mösker, Eva
AU - Faria, Raquel
AU - Süssmuth, Roderich D.
AU - Mendo, Sónia
AU - Caetano, Tânia
N1 - Funding Information:
Open access funding provided by FCT|FCCN (b-on). JB and TC were supported by Fundação para a Ciência e a Tecnologia—Ministério da Ciência, Tecnologia e Ensino Superior (Portugal), POPH, and European Union fellowships (SFRH/BD/97099/2013 and SFRH/BPD/77900/2011). TC (CEECIND/01463/2017) were also funded by national funds (OE), through FCT—Fundação para a Ciência e a Tecnologia, I.P., in the scope of the framework contract foreseen in the numbers 4, 5, and 6 of the article 23 of the Decree Law 57/2016, of August 29, changed by Law 57/2017, of July 19. RDS was supported by the Cluster of Excellence Unifying Systems in Catalysis. This work was funded by Coli4Lan project (FCOMP-01–0124-FEDER-027569); FCT-MCTES (PIDDAC); Fundo Europeu de Desenvolvimento Regional (FEDER), through the COMPETE—Programa Operacional Fatores de Competitividade (POFC); CESAM (UIDP/50017/2020 and UIDB/50017/2020 and LA/P/0094/2020); and FCT-MCTES through national funds, to the co-funding by the FEDER, within the PT2020 Partnership Agreement and Compete 2020.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/3
Y1 - 2023/3
N2 - The enzymatic machinery involved in the biosynthesis of lantibiotic is an untapped source of proteases with different specificities. Lanthipeptide biosynthesis requires proteolysis of specific target sequences by known proteases, which are encoded by contiguous genes. Herein, the activity of lichenicidin A2 (LicA2) trimming proteases (LicP and LicT) was investigated in vivo. Firstly, the impact of some residues and the size of the peptide were evaluated. Then followed trials in which LicA2 leader was evaluated as a tag to direct production and secretion of other relevant peptides. Our results show that a negatively charged residue (preferably Glu) at cleavage site is important for LicP efficacy. Some mutations of the lichenicidin hexapeptide such as Val-4Ala, Asp-5Ala, Asn-6Ser, and the alteration of GG-motif to GA resulted in higher processing rates, indicating the possibility of improved lichenicidin production in Escherichia coli. More importantly, insulin A, amylin (non-lanthipeptides), and epidermin were produced and secreted to E. coli supernatant, when fused to the LicA2 leader peptide. This work aids in clarifying the activity of lantibiotic-related transporters and proteases and to evaluate their possible application in industrial processes of relevant compounds, taking advantage of the potential of microorganisms as biofactories.
AB - The enzymatic machinery involved in the biosynthesis of lantibiotic is an untapped source of proteases with different specificities. Lanthipeptide biosynthesis requires proteolysis of specific target sequences by known proteases, which are encoded by contiguous genes. Herein, the activity of lichenicidin A2 (LicA2) trimming proteases (LicP and LicT) was investigated in vivo. Firstly, the impact of some residues and the size of the peptide were evaluated. Then followed trials in which LicA2 leader was evaluated as a tag to direct production and secretion of other relevant peptides. Our results show that a negatively charged residue (preferably Glu) at cleavage site is important for LicP efficacy. Some mutations of the lichenicidin hexapeptide such as Val-4Ala, Asp-5Ala, Asn-6Ser, and the alteration of GG-motif to GA resulted in higher processing rates, indicating the possibility of improved lichenicidin production in Escherichia coli. More importantly, insulin A, amylin (non-lanthipeptides), and epidermin were produced and secreted to E. coli supernatant, when fused to the LicA2 leader peptide. This work aids in clarifying the activity of lantibiotic-related transporters and proteases and to evaluate their possible application in industrial processes of relevant compounds, taking advantage of the potential of microorganisms as biofactories.
KW - Lanthipeptides
KW - Lantibiotics
KW - Site-directed mutagenesis
KW - Chimeric genes
KW - Recombinant peptides
KW - Proteases
UR - http://www.scopus.com/inward/record.url?scp=85147754019&partnerID=8YFLogxK
U2 - 10.1007/s00253-023-12388-5
DO - 10.1007/s00253-023-12388-5
M3 - Article
C2 - 36763118
SN - 0175-7598
VL - 107
SP - 1687
EP - 1696
JO - Applied Microbiology and Biotechnology
JF - Applied Microbiology and Biotechnology
IS - 5-6
ER -